[Vincamine concentrations in plasma and cerebrospinal fluid in patients following intravenous infusion (author's transl)].
The pharmacokinetic characteristics of 14,15-dihydro-14beta-hydroxy-(3alpha,16alpha)-eburnamenine-14-carbonic acid methylester (vincamine; Vincapront) were studied after i.v. infusion (30 or 40 mg vincamine-hydrochloride within 28--40 min, respectively) in 6 patients with cerebrovascular diseases. At the end of the infusion, maximum plasma levels ranged between 607 and 999 ng/ml. The decline of the plasma concentrations after the end of the infusion could be described using a two-compartment open model. After a phase of distribution lasting 1--2 h there was a linear elimination of vincamine in the semilogarithmic plot. The mean half-life for the beta-slope was 2 h. In four patients we measured the vincamine concentration in the cerebrospinal fluid 2 h after the end of the infusion. It amounted to only 5--24% of the simultaneously estimated plasma concentration.
D000328:Adult; D005260:Female; D006207:Half-Life; D006801:Humans; D007263:Infusions, Parenteral; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D013997:Time Factors; D014748:Vinca Alkaloids / Q000097:blood / Q000134:cerebrospinal fluid / Q000378:metabolism*
D014748:Vinca Alkaloids
Plasma- und Liquorspiegel von Vincamin nach intravenöser Infusion bei Patienten.